Benzodiazepine Site on Gamma-Aminobutyric Acid Type A Receptor

The benzodiazepine site is a specific allosteric modulatory binding site located on the gamma-aminobutyric acid type A (GABAA) receptor, a major inhibitory neurotransmitter receptor in the central nervous system. Benzodiazepines and related drugs exert their effects by binding to this site, thereby modulating GABAergic neurotransmission. The site is located at the interface between an α subunit (specifically α1, α2, α3, or α5) and a γ subunit (usually γ2) on the pentameric GABAA receptor complex. Benzodiazepines act as positive allosteric modulators, enhancing the receptor's response to GABA, increasing the frequency of chloride channel opening, and leading to greater chloride influx into neurons, resulting in hyperpolarization and enhanced inhibitory signaling. Different benzodiazepines have varying affinities for different alpha subunits, underlying differences in clinical effects. Their use must be carefully managed due to risks including tolerance and dependence.

Other names

BDZ receptorBenzodiazepine receptorGABAA receptor benzodiazepine siteBZ site

Positive allosteric modulation of GABAA receptor; increases frequency of chloride channel opening upon GABA binding.